Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability. With no disease-modifying treatments available or on the horizon, oral non-steroidal anti-inflammatory drugs (NSAIDs) are… read more.
Osteoporosis is so difficult to detect in early stage it’s called the “silent disease.” What if artificial intelligence could help predict a patient’s chances of having the bone-loss… read more.
Dairy isn’t the only food that’s good for bone health. Prunes may also protect bone structure and strength in postmenopausal women, according to a new study led by… read more.
Knee osteoarthritis (OA) is a common cause of pain and joint stiffness. And while physical activity is known to ease symptoms, only one in 10 people regularly exercise. Understanding… read more.
Osteoporosis, a condition characterized by porous and fragile bones, poses a significant threat to skeletal health. As the very framework of the human body, bones provide crucial structural… read more.
Birmingham researchers have shown PEPITEM, a naturally occurring peptide (small protein) holds promise as a new therapeutic for osteoporosis and other disorders that feature bone loss, with distinct… read more.
As part of the University of Colorado Department of Medicine’s annual Research Day, held on April 23, faculty member Christine Swanson, MD, MCR, described her National Institutes of Health-funded clinical research on whether adequate… read more.
UCB, announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jubbonti, intended for the… read more.
Sandoz, announced that the FDA approved Wyost (denosuab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines Keren Haruvi,… read more.
Current osteoarthritis treatment manages symptoms rather than addressing the underlying disease, but a new University of Adelaide study has shown the condition may be treatable and reversible. Osteoarthritis… read more.
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
